AC Immune SA - Form 20-F Summary (Fiscal Year Ended Dec 31, 2016)
Business Context and Reporting Period
Company: AC Immune SA (Swiss corporation, NASDAQ: ACIU)
Reporting Period: Fiscal year ended December 31, 2016
Business Model: Clinical-stage biopharmaceutical company focused on neurodegenerative diseases (Alzheimer's, Parkinson's) via proprietary SupraAntigen and Morphomer platforms.
Key Assets: Lead candidate crenezumab (anti-Abeta antibody, Phase 3 with Genentech), ACI-24 (anti-Abeta vaccine, Phase 1/2a), ACI-35 (anti-tau vaccine, Phase 1b with Janssen), and diagnostic PET tracers.
Accounting Basis: International Financial Reporting Standards (IFRS). Financials presented in Swiss Francs (CHF).
Key Financial Metrics
| Metric (CHF '000) | 2016 | 2015 |
|---|---|---|
| Total Revenue | 23,214 | 39,090 |
| Research & Development Expenses | (25,774) | (17,049) |
| General & Administrative Expenses | (7,896) | (3,417) |
| Operating Loss | (10,456) | 18,624 (Income) |
| Net Loss | (7,096) | 20,270 (Income) |
| Cash and Cash Equivalents (Year End) | 152,210 | 76,522 |
| Total Assets | 156,100 | 79,931 |
| Accumulated Deficit | (46,921) | (40,381) |
Note: 2015 included significant milestone revenues from Genentech ($25M crenezumab milestone + CHF 14M anti-tau milestone). 2016 revenue was lower due to the timing of milestone achievements.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 41% (CHF 15.9M) compared to 2015. This was driven by the absence of the large Genentech crenezumab milestone recognized in 2015, partially offset by a CHF 14M Genentech anti-tau milestone and Janssen ACI-35 milestones in 2016.
- Expense Increase: R&D expenses rose 51% (CHF 8.7M) due to increased investment in ACI-24 (manufacturing and clinical setup), ACI-35, and new discovery programs. G&A expenses more than doubled (CHF 4.5M increase) primarily due to costs associated with becoming a public company (legal, audit, investor relations) and share-based compensation.
- Liquidity Surge: Cash balances doubled from CHF 76.5M to CHF 152.2M, driven by net proceeds of approximately CHF 65.3M from the September 2016 Initial Public Offering (IPO).
- Profitability Shift: The company swung from a net profit of CHF 20.3M in 2015 to a net loss of CHF 7.1M in 2016.
Guidance, Outlook, and Risks
Outlook & Capital Resources: Management believes existing capital resources (CHF 152.2M cash) are sufficient to fund operations through at least the fourth quarter of 2018, excluding potential future milestone payments. The company expects to continue incurring significant operating losses as it advances clinical programs.
Key Risks & Contingencies:
- Internal Control Material Weakness: A material weakness in internal control over financial reporting, identified in 2014 regarding non-routine and complex accounting transactions, continued to exist as of December 31, 2016. This poses a risk of material misstatement in future financial reporting.
- Clinical Development Risk: Success depends heavily on crenezumab (Phase 3 with Genentech) and ACI-24/ACI-35. Failure in clinical trials or inability to obtain regulatory approval would materially harm the business.
- Collaboration Dependency: Reliance on partners (Genentech, Janssen, Piramal) for development and commercialization. Partners can terminate agreements with notice (e.g., Genentech has 3-month termination rights).
- Regulatory & Reimbursement: Uncertainty regarding FDA/EMA approval, pricing, and reimbursement for future products.
Investor Verification Checklist
- Remediation of Internal Controls: Verify the specific steps taken to remediate the material weakness in internal controls and whether it has been resolved in subsequent filings.
- Cash Burn Rate: Monitor quarterly cash burn to confirm the runway extends through Q4 2018 as projected, given the high R&D spend.
- Crenezumab Phase 3 Progress: Track enrollment and interim data from the CREAD Phase 3 trials conducted by Genentech, as this is the primary value driver.
- Milestone Timing: Review future revenue recognition policies regarding contingent milestone payments from Genentech, Janssen, and Piramal, as these create significant earnings volatility.
- Share-Based Compensation: Assess the impact of the new 2016 Stock Option and Incentive Plan on future dilution and expense.